Pathologic Diagnosis and Tumor Characterization

Pathologic diagnosis is the process by which a tumor specimen is examined and interpreted to establish what the tumor is, and tumor characterization is the further profiling of its morphology, immunophenotype, and molecular features. Together they convert tissue obtained by biopsy or resection into the structured diagnosis that anchors classification, grading, staging, and biomarker assessment.

Definition

Pathologic diagnosis is the determination of a tumor's identity through gross and microscopic examination of tissue, and tumor characterization is the supplementary assessment of its immunophenotypic and molecular features, yielding an integrated diagnosis that supports classification, grading, staging, and biomarker reporting.

Scope

The topic covers specimen acquisition and handling, gross and microscopic examination, ancillary techniques such as immunohistochemistry and molecular testing, the integration of these findings into an integrated diagnosis, and the role of synoptic reporting. It is a reference and educational account of how a tissue diagnosis is reached, not clinical guidance for any individual case.

Core questions

• How does a tissue specimen become a definitive tumor diagnosis?
• What do gross examination and microscopy each contribute?
• How do immunohistochemistry and molecular tests refine a diagnosis?
• What is an integrated (morphologic-molecular) diagnosis?
• Why are standardized synoptic pathology reports used?

Key concepts

• Biopsy and resection specimens
• Gross and microscopic examination
• Immunohistochemistry (immunophenotyping)
• Molecular and genetic testing
• Integrated diagnosis
• Synoptic (standardized) reporting
• Analytic standardization of assays

Mechanisms

Diagnosis proceeds from specimen handling and gross examination to microscopic interpretation, where morphology suggests an entity. Ancillary studies then refine it: immunohistochemistry establishes lineage and detects protein markers, while molecular and genetic testing detect defining alterations. These layers are combined into an integrated diagnosis that names the entity and reports grade, relevant biomarkers, and (for resections) extent. Standardized assays and synoptic templates make the resulting diagnosis reproducible and complete (Kumar, Abbas, & Aster, 2021; Travis et al., 2015; Wolff et al., 2018). Increasingly, classifications require molecular criteria alongside morphology, so characterization is integral to diagnosis rather than an optional add-on (WHO Classification of Tumours Editorial Board, 2019-).

Clinical relevance

The pathologic diagnosis is the reference point against which classification, grade, stage, and biomarker status are recorded and against which evidence is applied. As a reference topic it describes how a tissue diagnosis is constructed and characterized; it does not direct diagnostic or treatment decisions for an individual patient.

Epidemiology

Because cancer registration and outcome statistics are built on the pathologic diagnosis, the accuracy, completeness, and standardization of tumor characterization affect the quality of population-level cancer data. Synoptic reporting and validated assays improve the comparability of diagnoses across laboratories and over time (Wolff et al., 2018; WHO Classification of Tumours Editorial Board, 2019-).

Evidence & guidelines

Pathologic diagnosis is governed by tumor classification references (the WHO Classification of Tumours series), assay-specific testing guidelines (for example the ASCO/CAP HER2 guideline), and synoptic reporting protocols, which define diagnostic criteria, ancillary testing standards, and required reporting elements (Travis et al., 2015; Wolff et al., 2018; WHO Classification of Tumours Editorial Board, 2019-).

History

Tumor diagnosis began as purely morphologic surgical pathology and was progressively augmented through the twentieth century by histochemistry and then immunohistochemistry, which allowed lineage assignment beyond what morphology alone could resolve. The molecular era added genetic testing, and contemporary classifications such as the 2015 WHO lung classification and the fifth-edition WHO series formalize integrated morphologic-molecular diagnosis (Travis et al., 2015; WHO Classification of Tumours Editorial Board, 2019-).

Debates

How should morphologic and molecular findings be integrated when they disagree?

As classifications make molecular criteria part of the diagnosis, cases arise where morphology and molecular results point to different entities; defining rules for an integrated diagnosis, and for which markers are required, is an evolving area within tumor classification.

Seminal works

• travis-2015
• kumar-robbins-2021

Frequently asked questions

Why is a tissue biopsy usually needed to diagnose cancer?

Imaging and clinical findings can suggest a tumor, but a definitive diagnosis of cancer type, grade, and biomarker status generally requires microscopic and molecular examination of tissue obtained by biopsy or resection.

What is an integrated diagnosis?

An integrated diagnosis combines morphologic appearance with immunohistochemical and molecular findings into a single, defined tumor entity, which is increasingly required by modern classifications rather than relying on morphology alone.